

Maternal MTHFR A1298C polymorphism and risk of congenital heart disease in fetus

Vandana Rai

Department of Biotechnovogy

V B S Purvanchal University

Jaunpur-222003,UP

Correspondence: raivandana@rediffmail.com

Abstract:

Methylenetetrahydrofolate reductase (MTHFR) is an important enzyme involved in folate metabolism, DNA synthesis and methylation. A number of studies have examined the association of maternal MTHFR A1298C polymorphism with congenital heart disease (CHD) susceptibility; however, the conclusions were contradictory. To clarify the influence of maternal MTHFR A1298C polymorphism on CHD, a meta-analysis of seventeen case-control studies was carried out. Four electronic databases - Pubmed, Google Scholars, Elsevier and Springer Link were searched upto June, 2018 for suitable articles. The pooled odds ratios (ORs) with 95% confidence intervals (95% CIs) were used to evaluate the association. Meta-analysis was performed by Mix and MetaAnalyst programs. The results of meta-analysis suggested that except co-dominant model, maternal A1298C polymorphism is risk for CHD in fetus using overall comparisons in four genetic models (C vs. A: OR= 1.19, 95% CI= 1.00-1.41, p= 0.04; CC+AC vs. AA: OR= 1.19, 95% CI= 0.97-1.4, p= 0.04; CC vs. AA: OR= 1.46, 95% CI= 1.00-2.13, p= 0.04; AC vs. AA OR= 1.13, 95% CI=0.93-1.36, p= 0.23; CC vs. AC+AA: OR=1.34, 95% CI=1.1-1.6, p=0.01). Publication bias was absent using four genetic models. In conclusion, results of present meta-analysis showed significant association between maternal MTHFR A1298C polymorphism and CHD risk.

Keywords:

Congenital Heart Disease, CHD, MTHFR , A1298C, Polymorphism, Meta-analysis

Introduction:

Cardiac malformations rank among the most common congenital malformations. The incidence of congenital heart disease (CHD) is about 8 per 1000 live birth (Mitchell et al., 1971; Hofmann and Christianson, 1978; Winter et al.,2007) and are mainly due to incomplete development of the heart during pregnancy (Bozovic et al., 2011). Their origin is considered to be multifactorial, resulting from an interaction between genetic predisposition and environmental factors. Periconceptional folic acid, reduces the risk of CHD like -neural tube defects (NTD) (Czeizel and Dudas, 1992). Although the mechanism by which folic acid exerts its protective effect is unclear, the teratogenic process resulting from folate insufficiency may be related to hyperhomocysteinemia (Nelen, 2001; Vollset et al., 2000). Methylenetetrahydrofolate reductase (MTHFR) gene polymorphism is an important genetic factor for hyperhomocysteinemia (Sibani et al.,2000).

MTHFR is a critical enzyme in folate and methionine metabolism. It irreversibly catalyzes the reduction of 5,10-methylene-tetrahydrofolate to 5-methyltetrahydrofolate, which one is the methyl donor for the conversion of homocysteine to methionine (Goyette et al., 1994). Several folate pathway genes showed single nucleotide polymorphism (SNPs) and frequency of these polymorphisms varies greatly word wide (Rai et al.,2010,2012a,b,2013; Yadav et al., 2017). The MTHFR gene is located on chromosome 1p36.3. Among all the identified polymorphisms, C677T and A1298C polymorphisms are clinically important and variant MTHFR enzymes (Ala222Val and Glu429Ala) are associated with reduced enzyme activity and hyperhomocysteinemia (Frosst et al.,1995; Weisberg et al.,1998; Rozen,1997).

A1298C polymorphism involves A to C nucleotide substitution at 1298th position (Weisberg et al. 1998), leading to a glutamate to alanine substitution (Glu429Ala) in the MTHFR protein. Glutamate to alanine amino acid substitution at 429th position in MTHFR enzyme, reduces 40% enzyme activity. A1298C allele frequency differs greatly in various ethnic groups of the world. The prevalence of the A1298C homozygote variant genotype ranges from 7 to 12% in White populations from North America and Europe and lower frequencies have been reported in Hispanics (4 to 5 %) and Asian populations (1 to 4%) (Botto and Young, 2000). MTHFR A1298C gene polymorphism is associated with a number of diseases like- Down syndrome (Rai et al., 2006), neural tube defects (van der Put et al., 1997), cleft lip and palate (Chorna et al.,20011) and psychiatric disorders (Sazci et al., 2005) etc. Numerous case control studies were investigated the association between maternal MTHFR A1298C polymorphism and CHD but the results were contradictory. Hence, we performed meta-analysis of case control studies to conclude the role of maternal MTHFR A1298C polymorphism in fetal CHD risk.

Methods:

Article search was carried out in four electronic databases (Pubmed, Google scholar, Elsevier and Springer Link) up to June, 2018 using key terms - 'methylenetetrahydrofolate reductase or MTHFR', 'A1298C', 'polymorphism' and 'congenital heart disease or CHD'. Reference list of eligible articles were also searched for relevant studies.

Data selection:

Following data from each included article were extracted: author name; ethnicity; country of origin; journal name; year of publication; number of cases and controls; and number of MTHFR A1298C genotypes in mothers of CHD cases and mothers of healthy children as controls. **Inclusion and exclusion criteria:**

A strict inclusion and exclusion criteria was followed to select the studies for meta-analysis. Criteria for inclusion were as follows; (i) article should evaluated the association of maternal MTHFR A1298C gene polymorphism with CHD; (ii) article should be case-control association study; and (iii) the articles must report the sample size, distribution of alleles or genotypes for estimating the odds ratio (ORs) with 95% confidence interval (CIs). Studies were excluded if one of the following existed: (i) case-only studies, (ii) studies that contained duplicate data, and (iii) editorial, case reports or reviews.

Statistical analysis:

The present meta-analysis examined the overall association of maternal mutant C allele with the risk of CHD. The associations were indicated as odds ratios (ORs) with the corresponding 95% CI. The OR was estimated either by using fixed effects (Mantel and Haenszel, 1959) or random effects (DerSimonian and Laird, 1986) model depending upon heterogeneity. The heterogeneity between studies was tested using the Q-statistic and quantified by I^2 statistic (Higgins et al., 2002).

Sensitivity analysis:

The distribution of the genotypes in the control group was tested for Hardy Weinberg equilibrium (HWE) and sensitivity analysis performed by exclusion of the studies in which control population was not in HWE.

Publication bias:

Publication bias was investigated by using funnel plots of standard error and precision. Egger's regression intercept (Egger et al.,1997) was used to assess the publication bias. All p value were two sided, and p values <0.05 were considered statistically significant. All statistical analyses were performed using the computer program MIX version 1.7 (Bax et al., 2006) and MetaAnalyst (Wallace et al.,2013).

Results:

Characteristics of included studies:

Total seventeen studies (Storti et al.,2003; Nurk et al.,2004; Galdieri et al., 2007; Van Driel et al.,2008; Xu et al., 2010; Bozovic et al.,2011; Obermann-Borst et al.,2011; Weiner et al., 2012; Christense et al., 2013; Wang et al.,2013; Zidan et al.,2013; Huang et al.,2014; Sahiner et al.,2014; Li et al.,2015; Sayin et al.2015; Shi et al.,2015; Feng et al.,2016) were found suitable for the inclusion in present meta-analysis. The studies were published between 2003 and 2015. All these nine studies were performed in different countries- Brazil (Galdieri et al., 2007), China (Xu et al., 2010; Wang et al.,2013; Huang et al.,2014; Li et al.,2015; Sayin et al.2015; Shi et al.,2015; Feng et al.,2016), Croatia (Bozovic et al.,2011), Egypt (Zidan et al.,2013), Italy (Storti et al.,2003), Netherland (Obermann-Borst et al.,2011), Norway (Nurk et al.,2004; Van Driel et al.,2008), Russia (Weiner et al., 2011), Turkey (Sahiner et al.,2014), and USA (Christense et al., 2013). The lowest sample size was 25 (Nurk et al., 2004) and highest sample size was 502 (Xu et al., 2010) in included studies. Total number of cases were 2514 with genotype percentage of AA, AC and CC was 56.96%, 34.88% and 8.15% respectively. Total number of controls were 17,226 with genotypes percentage of AA, AC and CC were 47.53%, 42.51% and 9.95% respectively.

Meta-analysis:

In allele contrast meta-analysis, maternal mutant C allele showed significant association with CHD in fixed effect (OR= 1.14, 95%CI= 1.03-1.24, p= 0.007) and random effect (OR= 1.19, 95%CI= 0.95-1.36, p= 0.04) models (Table 2, Figure 1). Similar to allele contrast meta-analysis, pooled odds ratio for maternal mutant homozygote genotype (CC vs. AA) also showed significant association with CHD adopting both fixed (OR= 1.40, 95% CI= 1.11-1.46, p= 0.004) and random (OR= 1.46, 95%CI= 1.00-2.13, p= 0.04) effect models (Figure 2). Association of mutant heterozygous genotype (AC vs. AA; co-dominant model) did not show any association with CHD using fixed and random effect models. Dominant maternal mutant genotypes (CC+AC vs. AA; dominant model) showed significant association with CHD using both fixed (OR= 1.13; 95%CI= 1.0-1.26; p=0.04) and random (OR= 1.19; 95%CI= 0.97-1.4; p=0.04) effect models (Figure 3; Table 2). Meta-analysis using recessive genetic model (CC vs. AC+AA; recessive model) showed significant association with CHD with fixed (OR= 1.34; 95%CI= 1.1-1.6; p=0.01) and random (OR= 1.34; 95%CI= 0.99-1.81; p=0.28) effect models (Figure 4; Table 2).

A insignificant low heterogeneity existed in between studies for recessive model ($P_{\text{heterogeneity}}=0.06$, $I^2= 37.8\%$), significant heterogeneity existed between studies for allele contrast ($P_{\text{heterogeneity}}=0.0001$, $I^2= 65.04\%$), dominant model ($P_{\text{heterogeneity}}=0.0005$, $I^2= 61.34\%$), high heterogeneity existed between studies for homozygote ($P_{\text{heterogeneity}}=0.005$, $I^2= 53.68\%$), and co-dominant ($P_{\text{heterogeneity}}=0.006$, $I^2= 52.23\%$), comparisons.

Publication bias:

Funnel plots using standard error and precision values for allele and genotypes using random effect model were generated (Table 2; Figure 5,6). Symmetrical distribution of studies in the funnel plots suggests absence of

publication bias except co-dominant model. This is also supported by Eggers test ($p=0.29$ for C vs. A; $p=0.21$ for CC vs AA; $p=0.21$ for CC+AC vs. AA; $p=0.57$ for CC vs. AC+AA and $p=0.04$ for AC vs. AA) (Table 2).

Discussion:

Normal MTHFR activity is crucial to maintain the pool of circulating folate and methionine and to prevent the accumulation of homocysteine (Frosst et al., 1995). Numerous case control studies have indicated an effect of the maternal MTHFR genotype rather than that of the affected child (Martinelli et al, 2001; Prescott et al, 2002) on fetal development. The association of MTHFR polymorphisms with the increased risk of CHD supports the protective effect of maternal use of folic acid with respect to the occurrence of CHD.

Folate deficiency and hypofunction of MTHFR enzyme activity were affected cell proliferation and apoptosis in developing fetus. Embryonic heart development is a complex process and proliferation and apoptosis play important roles (Fisher et al., 2000; Gittenberger-de Groot et al.,2005; Li et al., 2005). Inadequate proliferation or excess apoptosis can directly or indirectly result in CHD(Kruman et al.,2005). However, it is not clear whether folate deficiency alters proliferation/ apoptosis in the heart or not (Li et al.,2005). MTHFR gene knock out mice have reduced concentration of S-adenosylmethionine and increased concentration of S-adenosylhomocysteine, showed hyperhomocysteinemia and global DNA hypomethylation (Chen et al., 2001)

Meta-analysis is a statistical tool which is successfully used for combining results of several small, low powered case control studies to conclude the results with less statistical error and high statistical power. Numerous meta-analyses were published to confirm the small effect of gene polymorphism as risk factor for several disease like cleft lip and palate (Rai,2014a,2018b); NTD (Yadav et al., 2015); male infertility (Rai and Kumar,2017d), Down syndrome (Rai,2011a; Rai et al.,2017c; Rai and Kumar,2018a); recurrent pregnancy loss (Rai,2016a), glucose 6-phosphate dehydrogenase deficiency (Kumar et al.,2016), bipolar disorder (Rai,2011b), Schizophrenia(Yadav et al.2016a, Rai et al.,2017e), autism (Rai,2016c; Rai and Kumar,2018c), Depression (Rai,2014c); Alzheimers disease (Rai,2016b,2017a); epilepsy (Rai and Kumar, 2018d), Uterine Leiomyoma (Kumar and Rai, 2018a), hyperurecemia (Rai,2016d), breast cancer (Rai,2014b; Rai et al.,2017b), esophageal cancer (Kumar and Rai, 2018b), lung cancer (Rai,2014d), prostate cancer (Yadav et al.,2016b),colorectal cancer (Rai,2015), digestive tract cancer (Yadav et al.,2018), endometrial cancer (Kumar and Rai, 2018c) and ovary cancer (Rai,2016e).

There are several limitations in current meta-analysis, which should be acknowledged- (i) unadjusted OR was used as association measure, (ii) only one gene polymorphism (MTHFR A1298C) was considered in present meta-analysis, (iii) only four databases were searched for studies, and (iv) gene- gene and gene -environmental interactions were not considered.

In conclusion, results of meta-analysis showed that maternal MTHFR A1298C polymorphism is a risk factor for congenital heart defects in fetus. Periconceptional intake of folate reduces the risk of congenital defects, because it donates methyl group for conversion of homocysteine to methionine and protect fetus from the teratogenic effect of higher concentration of homocysteine. Simultaneously methionine donates methyl group to S-adenosylmethionine for cellular methylation reactions in fetus and due to reduced MTHFR enzyme activity genomic hypomethylation occurs which affects gene expression in developing fetus. In future, larger studies from different regional as well as different ethnic population are required to find out the exact effect of maternal MTHFR A1298C polymorphism on fetal heart.

Conflict of interest: None

References:

Bax L, Yu LM, Ikeda N, Tsuruta H, Moons KG (2006) Development and validation of MIX: comprehensive free software for meta-analysis of causal research data. *BMC Med Res Methodol* 6: 50-52.

Botto LD, Young Q (2000) 5,10-Methylenetetrahydrofolate reductase gene variants and congenital anomalies: a HuGE review. *Am J Epidemiol* 151(9):862-77.

Bozovic IB, Vranekovic J, Cizmarevic NS, Mahulja-Stamenkovic V, Prpic I, Brajenovic-Milic B (2011) MTHFR C677T and A1298C polymorphisms as a risk factor for congenital heart defects in Down syndrome. *Pediatr Int* 53: 546–550.

Chen Z, Karaplis AC, Ackerman SL, Pogribny IP, Melnyk S, et al. (2001) Mice deficient in methylenetetrahydrofolate reductase exhibit hyperhomocysteinemia and decreased methylation capacity, with neuropathology and aortic lipid deposition. *Hum Mol Genet* 10: 433–443.

Chorna LB, Akopyan HR, Makukh HV, Fedoryk IM (2011) Allelic Polymorphisms in the MTHFR, MTR and MTRR genes in patients with cleft lip and/or palate and their mothers. *Cytology and Genetics* 45: 177–181.

Christensen KE, Deng L, Leung KY, Arning E, Bottiglieri T, Malysheva OV, Caudill MA, Krupenko NI, Greene ND, Jerome-Majewska L, MacKenzie RE, Rozen R (2013) A novel mouse model for genetic variation in 10-formyltetrahydrofolate

synthetase exhibits disturbed purine synthesis with impacts on pregnancy and embryonic development. *Hum Mol Genet* 22(18):3705-19.

Christensen KE, Zada YF, Rohlicek CV, Andelfinger GU, Michaud JL, Bigras JL, Richter A, Dube MP, Rozen R (2013) Risk of congenital heart defects is influenced by genetic variation in folate metabolism. *Cardiol Young* 23:89-98.

Czeizel AE, Dudas I (1992) Prevention of the first occurrence of neural-tube defects by periconceptional vitamin supplementation. *N Engl J Med* 327: 1832–1835.

DerSimonian R, Laird N (1986) Meta-analysis in clinical trials. *Control Clin Trials* 7: 177–88.

Egger M, Davey Smith G, Schneider M, Minder C (1997) Bias in meta-analysis detected by a simple, graphical test. *BMJ* 315: 629–634.

Feng ZS, Zhao MC, Wang L, Li GX, Tao SG, Wen LL, Wang K, Ma XJ (2016) The investigation of correlation between MTHFR gene polymorphism and congenital heart disease by means of GeXP multiplex analysis technique. *J Hebei Med* 38:1143-1146.

Fisher SA, Langille BL, Srivastava D (2000) Apoptosis during cardiovascular development. *Circ Res* 87:856–64.

Frosst P, Blom H J, Milos R, Goyette P, Sheppard C A, Matthews R G, Boers GJH, Heijer M, Kluijtmans LAJ, Heuve LP, Rozen R (1995) A candidate genetic risk factor for vascular disease: A common mutation in methylenetetrahydrofolate reductase. *Nat Genet* 10(1):111-3.

Galdieri LC, Arrieta SR, Silva CM, Pedra CA, D'Almeida V (2007) Homocysteine concentrations and molecular analysis in patients with congenital heart defects. *Arch Med Res* 38 : 212–218.

Gittenberger-de Groot AC, Bartelings MM, Deruiter MC, Poelmann RE (2005) Basics of cardiac development for the understanding of congenital heart malformations. *Pediatr Res* 57:169–76.

Goyette P, Sumner JS, Milos R, Duncan AM, Rosenblatt DS, Matthews RG, Rozen R (1994) Human methylenetetrahydrofolate reductase: isolation of cDNA, mapping and mutation identification. *Nat Genet* 7(2):195-200.

Higgins J, Thompson S, Deeks J, Altman D (2002) Statistical heterogeneity in systematic reviews of clinical trials: A critical appraisal of guidelines and practice. *J Health Serv Res Policy* 7: 51–61.

Hofmann JIE, Christianson R (1978) Congenital heart disease in a cohort of 19,502 births with long-term follow up. *Am J Cardiol* 42: 641–647.

Huang J, Mei J, Jiang L, Jiang Z, Liu H, Ding F (2014) MTHFR rs1801133 C>T polymorphism is associated with an increased risk of tetralogy of Fallot. *Biomed Rep* 2:172-176.

Kruman II, Mouton PR, Emokpae R, Cutler RG, Mattson MP (2005) Folate deficiency inhibits proliferation of adult hippocampal progenitors. *Neuroreport* 16:1055–1059.

Kumar P, Yadav U, Rai V (2015) Methylenetetrahydrofolate reductase gene C677T polymorphism and breast cancer risk: Evidence for genetic susceptibility. *Meta Gene* 6 : 72–84.

Kumar P, Yadav U, Rai V (2016) Prevalence of glucose 6-phosphate dehydrogenase deficiency in India: An updated meta-analysis. *Egypt J Med Hum Genet* 17:295-302.

Kumar, P., Rai, V. 2018. Catechol-O-Methyltransferase Val158Met polymorphism and susceptibility to Uterine Leiomyoma. *Jacobs Journal of Gynecology and Obstetrics*, 2018a; 5(1): 043.

Kumar P, Rai V. Methylenetetrahydrofolate reductase C677T polymorphism and risk of esophageal cancer: An updated meta-analysis. *Egypt J Med Hum Genet*. 2018b; 19(4): 273-284.

Kumar, P., Singh, G., Rai, V. 2018. Evaluation of COMT gene rs4680 polymorphism as a risk factor for endometrial cancer. *IJCB*, 2018c; 10.1007/s12291-018-0799-x.

Li D, Pickell L, Liu Y, Wu Q, Cohn JS, Rozen R (2005) Maternal methylenetetrahydrofolate reductase deficiency and low dietary folate lead to adverse reproductive outcomes and congenital heart defects in mice. *Am J Clin Nutr* 82:188–95.

Li Z, Jun Y, Zhong-Bao R, Jie L, Jian-Ming L (2015) Association between MTHFR C677T polymorphism and congenital heart disease. A family-based meta-analysis. *Herz* 40:S160-167.

Mantel N, Haenszel W (1959) Statistical aspects of the analysis of data from retrospective studies of disease. *J Natl Cancer Inst* 22(4): 719-48.

Martinelli P, Grandone E, Colaizzo D, Paladini D, Sciannamé N, Margaglione M, Di Minno G (2001) Familial thrombophilia and the occurrence of fetal growth restriction. *Haematologica* 86(4):428-31.

Mitchell SC, Korones SB, Berendes HW (1971).. Congenital heart disease in 56,109 births. Incidence and natural history. *Circulation* 43: 323–332.

Nelen WL (2001) Hyperhomocysteinaemia and human reproduction. *Clin Chem Lab Med* 39(8): 758–763.

Nurk E, Tell GS, Refsum H, Ueland PM, Vollset SE (2004) Associations between maternal methylenetetrahydrofolate reductase polymorphisms and adverse outcomes of pregnancy: The Hordaland Homocysteine Study. *Am J Med* 117: 26–31.

Obermann-Borst SA, van Driel LM, Helbing WA, de Jonge R, Wildhagen MF, Steegers EA, Steegers-Theunissen RP (2011) Congenital heart defects and biomarkers of methylation in children: a case-control study. *Eur J Clin Invest* 41:143-150.

Prescott NJ, Winter RM, Malcolm S (2002) Maternal MTHFR genotype contributes to the risk of non-syndromic cleft lip and palate. *J Med Genet* 39(5):368-9.

Rai V, Yadav U, Kumar P, Yadav SK (2010) Methylenetetrahydrofolate reductase polymorphism (C677T) in Muslim population of Eastern Uttar Pradesh, India. *Ind J Med Sci* 64(5): 219-223.

Rai V (2011a) Polymorphism in folate metabolic pathway gene as maternal risk factor for Down syndrome. *Int J Biol Med Res* 2(4): 1055-1060.

Rai V (2011b) Evaluation of methylenetetrahydrofolate reductase gene variant (C677T) as risk factor for bipolar disorder. *Cell Mol Biol* 57:1558- 1566.

Rai AK, Singh S, Mehta S, Kumar A, Pandey LK, Raman R (2006) MTHFR C677T and A1298C polymorphisms are risk factors for Down's syndrome in Indian mothers. *J Hum Genet* 51:278-283.

Rai V, Yadav U, Kumar P (2012a) Genotype prevalence and allele frequencies of 5,10-methylenetetrahydrofolate reductase (MTHFR) C677T mutation in two caste groups of India. *Cell Mol Biol* 58: OL1695- 701.

Rai V, Yadav U and Kumar P (2012b) MTRR A66G polymorphism among two caste groups of Uttar Pradesh (India). *Ind J Med Sci* 66:136-40.

Rai V, Yadav U, Kumar P, Yadav SK (2013) Analysis of methionine synthase reductase polymorphism (A66G) in Muslim population. *Ind J Hum Genet* 19:183-187.

Rai V (2014a) Maternal methylenetetrahydrofolate reductase (MTHFR) gene A1298C polymorphism and risk of nonsyndromic Cleft lip and/or Palate (NSCL/P) in offspring: A meta-analysis. *Asian J Medical Sciences* 6 (1):16- 21.

Rai V (2014b) Methylenetetrahydrofolate reductase A1298C polymorphism and breast cancer risk: a meta-analysis of 33 studies. *Annals of Medical and Health Sciences Research* 4 (6): 841-851.

Rai V (2014c) Genetic polymorphisms of methylenetetrahydrofolate reductase (MTHFR) gene and susceptibility to depression in Asian population: a systematic meta-analysis. *Cell Mol Biol* 60 (3): 29-36.

Rai V (2014d) Folate pathway gene MTHFR C677T polymorphism and risk of lung cancer in Asian populations. *Asian Pac J Cancer Prev* 15: 9259-64.

Rai V (2015) Evaluation of the MTHFR C677T polymorphism as a risk factor for colorectal cancer in Asian populations. *Asian Pac J Cancer Prev* 16 (18): 8093-8100 .

Rai V (2016a) Methylenetetrahydrofolate reductase C677T polymorphism and recurrent pregnancy loss risk in Asian population: a meta-analysis. *Ind J Clin Biochem* 31:402-413.

Rai V (2016b) Folate pathway gene methylenetetrahydrofolate reductase C677T polymorphism and Alzheimer disease risk in Asian population. *Ind J Clin Biochem* 31(3):245-52.

Rai V (2016c) Association of methylenetetrahydrofolate reductase (MTHFR) gene C677T polymorphism with autism: evidence of genetic susceptibility. *Metab Brain Disease* 31: 727-735.

Rai V (2016d) The MTHFR C677T polymorphism and hyperuricemia Risk: a meta-analysis of 558 cases and 912 controls. *Metabolomics* 6: doi.org/10.4172/2153-0769.1000166.

Rai V (2016e) Methylenetetrahydrofolate reductase gene C677T polymorphism and its association with ovary cancer. *J Health Med Informat* 7: 3, doi.org/10.4172/2157-7420.1000226.

Rai V (2017a) Methylenetetrahydrofolate reductase (MTHFR) C677T polymorphism and Alzheimer disease risk: a meta-analysis. *Mol Neurobio* 54:1173-1186.

Rai V, Yadav U, Kumar P (2017b) Impact of catechol-O-Methyltransferase Val 158Met (rs4680) polymorphism on breast cancer susceptibility in Asian population. *Asian Pac J Cancer Prev* 18 (5): 1243-1250.

Rai V, Yadvu U, Kumar P (2017c) Null association of maternal MTHFR A1298C polymorphism with Down syndrome pregnancy: An updated meta-analysis. *Egyptian J Med Hum Genet* 18(1): 9-18.

Rai V, Kumar P (2017d) Methylenetetrahydrofolate reductase C677T polymorphism and risk of male infertility in Asian population. *Ind J Clin Biochem* 32(3): 253-260.

Rai V, Yadav U, Kumar P, Yadav SK, Gupta S (2017e) Methylenetetrahydrofolate reductase A1298C genetic variant and risk of schizophrenia: an updated meta-analysis. *Indian J Med Res* 145(4):437.

Rai V, Kumar P (2018a) Fetal MTHFR C677T polymorphism confers no susceptibility to Down Syndrome: evidence from meta-analysis. *Egyptian J Med Hum Genet* .19:53-58.

Rai V (2018b) Strong association of C677T polymorphism of methylenetetrahydrofolate reductase gene with nosyndromic cleft lip/palate (nsCL/P). *Ind J Clin Biochem* 33(1):5-15.

Rai V, Kumar P (2018c) Methylenetetrahydrofolate reductase A1298C polymorphism and autism susceptibility. *Austin Journal of Autism & Related Disabilities* 4: 1048-1053.

Rai, V., Kumar, P. 2018. Methylenetetrahydrofolate reductase C677T polymorphism and susceptibility to epilepsy. *Neurol Sci*. 2018d; 10.1007/s10072-018-3583-z.

Rozen R (1997) Genetic predisposition to hyperhomocysteinemia: deficiency of methylenetetrahydrofolate reductase (MTHFR). *Thromb Haemost* 78: 523– 526.

Sahiner UM, Alanay Y, Alehan D, Tuncbilek E, Alikasifoglu M (2014) Methylene tetrahydrofolate reductase polymorphisms and homocysteine level in heart defects. *Pediatr Int* 56:167-172.

Sazci A, Ergul E, Kucukali I, Kara I, Kaya G (2005) Association of the C677T and A1298C polymorphisms of methylenetetrahydrofolate reductase gene with schizophrenia: association is significant in men but not in women. *Prog Neuropsychopharmacol Biol Psychiatry* 29(7): 1113-1123.

Sayin Kocakap BD, Sanli C, Cabuk F, Koc M, Kutsal A (2015) Association of MTHFR A1298C polymorphism with conotruncal heart disease. *Cardiol Young* 25:1326-1331.

Shi H, Yang S, Liu Y, Huang P, Lin N, Sun X, Yu R, Zhang Y, Qin Y, Wang L (2015) Study on Environmental Causes and SNPs of MTHFR, MS and CBS Genes Related to Congenital Heart Disease. *PloS One* 10:e0128646.

Sibani S, Christensen B, O’Ferrall E, Saadi I, Hiou-Tim F, Rosenblatt DS, Rozen R (2000) Characterization of six novel mutations in the methylenetetrahydrofolate reductase (MTHFR) gene in patients with homocystinuria. *Hum Mutat* 15: 280–287.

Storti S, Vittorini S, Lascone M R, Sacchelli M, Collavoli A, Ripoli A, Cocchi G, Biagini A, Clerico A (2003) Association between 5,10-methylenetetrahydrofolate reductase C677T and A1298C polymorphisms and conotruncal heart defects. *Clin Chem Lab Med* 41: 276–280.

van der Put NM, Eskes TK, Blom HJ (1997) Is the common 677CT mutation in the methylenetetrahydrofolate reductase gene a risk factor for neural tube defects? A meta-analysis. *Q J Med* 90:111-115.

van Driel LM, Verkleij-Hagoort AC, de Jonge R, Uitterlinden AG, Steegers EA, van Duijn CM, Steegers- Theunissen RP (2008) Two MTHFR polymorphisms, maternal B-vitamin intake, and CHDs. *Birth Defects Res A Clin Mol Teratol* 2008;82:474-481.

Vollset SE, Refsum H, Irgens LM, Emblem BM, Tverdal A, Gjessing HK, Monsen AL, Ueland PM (2000) Plasma total homocystein, pregnancy complications, and adverse pregnancy outcomes: the hordaland homocysteine study. *Am J Clin Nutr* 71: 962–968.

Wallace BC, Dahabreh IJ, Trikalinos TA, Lau J, Trow P, Schmid CH (2013) Closing the Gap Between Methodologists and End-Users: R as a Computational Back-end. *J Stat Software* 49:1-15.

Wang B, Liu M, Yan W, Mao J, Jiang D, Li H, Chen Y (2013) Association of SNPs in genes involved in folate metabolism with the risk of congenital heart disease. *J Matern Fetal Neonatal Med* 26:1768-1777.

Weiner AS, Gordeeva LA, Voronina EN, Boyarskikh UA, Shabaldin AV, Filipenko ML (2012) Polymorphisms in folate-metabolizing genes and risk of having an offspring with congenital anomalies in the West Siberian region of Russia: a case-control study. *Prenat Diagn* 32(11):1041-8.

Weisberg I, Tran P, Christensen B, Sibani S, Rozen R (1998) A second genetic polymorphism in methylenetetrahydrofolate reductase (MTHFR) associated with decreased enzyme activity. *Mol Genet Metab* 64: 169–172.

Winter S, Hafner E, Stonek F, Stuempflen I, Metzenbauer M, Philipp K (2007) Association of congenital cardiac defects and the C677T methylenetetrahydrofolate reductase polymorphism. *Prenat Diagn* 27: 704–708.

Xu J, Xu X, Xue L, Liu X, Gu H, Cao H, Qiu W, Hu Z, Shen H, Chen Y (2010) MTHFR c.1793G>A polymorphism is associated with congenital cardiac disease in a Chinese population. *Cardiol Young* 20: 318-326.

Yadav U, Kumar P, Yadav SK, Mishra OP, Rai V (2015) Polymorphisms in folate metabolism genes as maternal risk factor for Neural Tube Defects: an updated meta-analysis. *Metabolic Brain Disease* 30:7-24.

Yadav U, Kumar P, Gupta S, Rai V (2016a) Role of MTHFR C677T gene polymorphism in the susceptibility of schizophrenia: An updated meta-analysis. *Asian J Psychiatry* 20: 41–51.

Yadav U, Kumar P, Rai V (2016b) Role of MTHFR A1298C gene polymorphism in the etiology of prostate cancer: a systematic review and updated meta-analysis. *Egypt J Med Hum Genet* 17(2): 141-148.

Yadav U, Kumar P, Gupta S, Rai V (2017) Distribution of MTHFR C677T gene polymorphism in healthy North Indian population and an updated meta-analysis. *Ind J Clinical Biochem* 32(4):399-410.

Yadav U, Kumar P, Rai V (2018) NQO1 gene C609T polymorphism (dbSNP: rs1800566) and digestive tract cancer risk: A Meta analysis. *Nutrition and Cancer* 10.1080/01635581.2018.1460674.

Zidan HE, Rezk NA, Mohammed D (2013) MTHFR C677T and A1298C gene polymorphisms and their relation to homocysteine level in Egyptian children with congenital heart diseases. *Gene* 529(1):119-24.

Table 1. Distribution of different MTHFR A1298C genotypes in seventeen included meta-analysis

Study	Population	Control	Case	Case genotype			Control Genotype			HWE P-value
				AA	AC	CC	AA	AC	CC	
Storti et al.,2003	Italy	200	103	49	46	8	101	86	13	0.34
Nurk et al.,2004	Norway	14474	25	9	13	3	6607	6342	1525	0.95
Galdieri et al., 2007	Brazil	26	47	26	17	4	15	10	1	0.67
Van Driel et al.,2008	Norway	251	230	104	102	24	116	104	31	0.31
Xu et al.,2010	China	527	502	316	168	18	326	185	16	0.09
Bozovic et al.,2011	Croatia	55	52	21	27	4	27	27	1	0.05
Obermann-Borst et al.,2011	Netherland	183	139	69	57	13	75	90	18	0.23
Weiner et al., 2012	Russia	362	48	33	13	2	168	152	42	0.39
Christense et al., 2013	USA	65	182	98	71	13	36	22	7	0.21
Zidan et al.,2013	Egypt	80	80	13	32	35	33	25	22	0.001
Wang et al.,2013	China	188	170	115	45	10	133	47	8	0.22
Huang et al.,2014	China	208	170	111	56	3	146	56	6	0.82
Sahiner et al.,2014	Turkey	93	137	45	68	24	31	54	8	0.22
Li et al.,2015	China	150	150	114	36	0	131	19	0	0.41
Sayin et al.2015	Turkey	99	69	20	36	13	51	37	11	0.29
Shi et al.,2015	China	216	153	95	39	19	157	53	6	0.055
Feng et al.,2016	China	49	257	194	51	12	35	14	0	0.24

Table 2: Summary estimates for the odds ratio (OR) of MTHFR A1298C in various allele/genotype contrasts, the significance level (p value) of heterogeneity test (Q test), and the I² metric and publication bias p-value (Egger Test).

Genetic Models	Fixed effect OR (95% CI), p	Random effect OR (95% CI), p	Heterogeneity p-value (Q test)	I ² (%)	pvalue of Egger's test
Allele Contrast (C vs A)	1.14(1.03-1.24),0.007	1.19(1.00-1.41),0.04	0.0001	65.04	0.29
Co-dominant (AC vs AA)	1.1(0.96-1.22),0.20	1.13(0.93-1.36),0.23	0.006	52.23	0.04
Homozygote (CC vs AA)	1.40(1.11-1.46),0.004	1.46(1.00-2.13),0.04	0.005	53.68	0.21
Dominant (CC+ AC vs AA)	1.13(1.0-1.26),0.04	1.19(0.97-1.4),0.04	0.0005	61.34	0.22
Recessive (CC vs AC+AA)	1.34(1.1-1.6),0.01	1.34(0.99-1.81),0.02	0.06	37.8	0.57




Figure 1: Forest plots (random effect) of allele contrast model (C versus A) showed significant association between maternal MTHFR A1298C polymorphism and CHD risk.




Figure 2: Forest plots (random effect) of homozygote model (CC versus AA) showed significant association between maternal MTHFR A1298C polymorphism and CHD risk.




Figure 3: Forest plots (random effect) of dominant model (CC + AC versus AA) showed significant association between maternal MTHFR A1298C polymorphism and CHD risk.




Figure 4: : Forest plots (random effect) of recessive model (CC versus AC+AA) showed significant association between maternal MTHFR A1298C polymorphism and CHD risk.




Figure 5: Funnel plots of precision by OR of MTHFR A1298C allele contrast




Figure 6. Funnel plots of standard error by OR of MTHFR A1298C allele contrast